Saturday 03.11.2007

Workshop Scientific Session Satellite Symposium Main Program
Session details 14:00–15:30
Workshop 1 (Parallel Sessions)

Cancer Survivorship

Room:Pipin II (Dorint Hotel)
  • 14:00

    Myocardial Infarction Mortality Risk after Treatment for HL: a Collaborative British Cohort Study

  • Risk Factors for Cardiovascular Disease; Dutch Results

  • Clinical Applications of Modelled Second Cancer Risk Among HL Survivors

  • Breast Tumors Induced by High-dose Radiation Display Similar Genetic Profiles

  • Screening for Lung Cancer in Patients at High Risk of this Second Cancer after Treatment for HL

  • Breast Cancer Screening with MRI in Female HL Survivors

Session details 14:00–15:30
Workshop 2 (Parallel Sessions)

Pathology

Room:Pipin I (Dorint Hotel)
  • 14:00

    Cytokine Gene Expression and T-Cell Transcription Factor Profile of the T-Cells of the Nodular Lymphocyte Predominance Type of HL

  • Double-Positive CD4+CD8+ T-Cell Populations in Nodular Lymphocyte Predominant HL: Further Characterization and Relationship to Other Entities

  • CD4/CD8-double Positive T-Cells in Nodular Lymphocyte Predominance HL

  • Regulatory T-Cells in Classical HL

  • Biologic Prognostic Markers in cHL: Evaluation of Characteristics of RS Cells as well as the Tumor Infiltrating Lymphocytes

  • dentification and Purification of Hodgkin Cells from Lymph Nodes Involved by Classical HL by Flow Cytometry and Flow Cytometric Cell Sorting

Session details 14:00–15:30
Workshop 3 (Parallel Sessions)

Allogeneic Stem Cell Transplantation

Room:Martin & Augustin (Dorint Hotel)
  • 14:00

    Allogeneic Hematopoietic Cell Transplantation for HL

  • Allogeneic Stem Cell Transplantation (Allo-SCT) in HL: The European Point of View

  • Improved Outcome Following Reduced Intensity Allogeneic Transplantation in HL Relapsing Post-Autologous Transplantation

  • Allogeneic/Syngeneic/Autologous Transplantation – a Comparison

Session details 14:00–15:30
Workshop 4 (Parallel Sessions)

Pædiatric Hodgkin Lymphoma

Room:Severin (Dorint Hotel)
  • 14:00

    Current Protocols and Concepts in the USA

  • Strategy of the EuroNet-PHL-C1 Protocol for the Treatment of Classical HL in Children and Adolescents

  • First International Inter-Group Study for Lymphocyte Predominant HL in Children and Adolescents

  • Current Children’s Oncology Group (COG) Protocol for LPHL

Session details 16:00–17:30
Workshop 5

Future Studies / Intergroup Trials

Room:Pipin II (Dorint Hotel)
  • 16:00

    The new trial generation of the German Hodgkin Study Group (GHSG)

  • The H10 EORTC/GELA Randomized Intergroup Trial on Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supradiaphragmatic Stage I/II HL

  • Response-Adapted Therapy Using FDG-PET Scanning after Initial ABVD: The UK NCRI, Italian and Nordic Trial in Advanced HL

  • Identification of Relevant and Practical Questions for an Transatlantic Intergroup Designs

  • Development of ABVD as Standard Treatment for HL

  • Organisation Central On-line PET Review

Session details 16:00–18:00
Scientific Session 1

Chronic Inflammation

Room:Isabellensaal

Sunday 04.11.2007

Workshop Scientific Session Satellite Symposium Main Program
Session details 08:30–10:00
Scientific Session 2

Characterization of HRS Cells and "Stem Cells" in HL

Room:Großer Saal
  • 08:30

    Molecular Immunogenetics of B Cells and HRS Cells

  • Translocations in HRS Cells

  • The Plasticity of HRS Cells

  • The Role of microRNA for Regulation of PRDM1/Blimp-1in HRS Cells

  • BIC and other miRNAs in HL

  • HL: Evidence for a Cancer Stem Cell and Therapeutic Implications

  • Induction of Hodgkin-like Phenotype by Epigenetic Reprogramming of B Cells

  • 3D Nuclear Organization of Telomeres in HRS Cells

Session details 10:30–12:00
Scientific Session 3

Scientific Session on Translational Approaches

Room:Großer Saal
  • 10:30

    Antiangiogenic Agents

  • KLHDC8B: a Candidate HL Susceptibility Gene

  • Analysis of Genetic Predisposition to Hematotoxicity in HL

  • Serum Profiling of Cytokines

  • Targeted Treatment Approaches in HL

  • How to Select Novel Small Molecules for Early Clinical Testing

  • Proteomics Analysis of HL: Identification of New Players Involved in the Cross Talk between HRS Cells and Infiltrating Lymphocytes

  • Galectin 1 Mediates Tumor Escape in HL

Session details 12:15–13:45
Satellite Symposium

Prophylaxis and Treatment of Side Effects of Chemotherapy: Casuistic Forum

Room:Großer Saal
Session details 14:00–15:30
Satellite Symposium

Innovative Strategies in the Therapy of Hematological Malignancies

Room:Großer Saal
  • 14:00

    Velcade – Lead Compound in Multiple Myeloma?

  • Future Directions in the Treatment of MDS

  • Velcade – Innovative Therapy Options in NHL

  • Efficient Hb Management in Lymphoma: Results of the HD15 Protocol

Session details 16:00–17:30
Satellite Symposium

Treatment of Lymphomas: Current Strategies and Future Outlook

Room:Großer Saal
  • 16:00

    Pathogenesis of B-Cell Lymphomas and Identification of Molecules Suitable for Targeted Therapy

  • Review of Immuno-Chemotherapy in Aggressive and Follicular Lymphoma

  • State of the Art Therapy Non Hodgkin Lymphoma in the USA

  • Role of Immuno-Chemotherapy in HL

  • New treatment approaches in Aggressive Lymphoma: Intensified Immuno-Chemotherapy - Anti-VEGF + Immuno-Chemotherapy

  • New Treatment Approaches in HL: Emergence of Anti-VEGF as a New Modality in HL

Session details 17:30–20:00
Main Program

Opening Ceremony

Room:Großer Saal
  • 17:30

    From the Absorbent Gland to the “Molecular Cure” of Hodgkin Lymphoma

Session details 20:00
Main Program

Kick-off party

Room:Weinkeller

Monday 05.11.2007

Workshop Scientific Session Satellite Symposium Main Program
Session details 08:30–10:00
Scientific Session 4

Survivorship

Room:Großer Saal
  • 08:30

    Screening in High Risk Groups

  • Pulmonary and Cardiac Toxicity in HL Survivors

  • How to Preserve Fertility in HL Patients

  • Efficacy and Toxicity of Treatment of HL /Mature Data from a Single Centre

  • Causes of Death and Excess Mortality after HL: the EORTC-GELA Experience

  • Survival Patterns among HL Patients with a Family History of Lymphoma

Session details 10:30–12:00
Scientific Session 5

Early Stage HL

Room:Großer Saal
  • 10:30

    Defining the Role of Radiation Therapy (RT)

  • Chemotherapy Only

  • Combined Modality Approaches

  • Results of the EORTC-GELA H9 Randomized Trials: the H9-F Trial (Comparing 3 Radiation Dose Levels) and H9-U Trial (Comparing 3 Chemotherapy Schemes) in Patients with Favorable or Unfavorable Early Stage HL

  • Stage I/II HL with Bulky Mediastinal Disease or other Risk Factors; The Stanford V Experience

  • Chemotherapy is Essential for Optimal Treatment of Limited Stage Nodular Lymphocyte Predominant HL

Session details 12:15–13:45
Satellite Symposium

Procarbazine: An Established Drug with a New Life

Room:Großer Saal
  • 12:15

    Hodgkin Lymphoma: Better Cure with or without Procarbazine?

  • Therapy of primary CNS-Lymphomas: What’s new?

  • Molecular Predictors and Prognostic Markers in Brain Tumours.

  • What can we learn from Randomized Trials with Patients with Anaplastic Gliomas?

  • Investing in the Future of Cancer Patients

  • Summary and Closing Remarks

Session details 14:00–15:30
Scientific Session 6

Relapsed and Refractory Disease

Room:Großer Saal
  • 14:00

    GHSG Trials in Relapsed HL

  • The Role of Gemcitabine in the Treatment of Primary and Relapsed Disease

  • New Agents

  • Ifosfamide, Gemcitabine, Vinorelbine, Prednisolone (IGEV) and Fixed Dose of Lenograstim: an Effective Mobilization Regimen in Pretreated HL Patients

  • A Phase II Study of MGCD0103, a Novel Oral Isotype-Selective Histone Deacetylase Inhibitor, in Patients with Relapsed or Refractory HL

  • Promising Results for Patients with Relapsed or Refractory HL Treated with the Oral mTOR Inhibitor Everolimus (RAD001)

Session details 16:00–17:30
Scientific Session 7

Translational Research

Room:Großer Saal
  • 16:00

    Biological Risk Factors for Stratification of HL Patients

  • The Role of the Microenvironment in HL

  • Analysing Differential Gene Expression and Genetic Lesions in HRS and L&H Cells to Identify New Therapeutic Targets

  • Latent EBV Infection of HRS Cells Predicts Adverse Outcome in Older Adult Classical HL Patients

  • A Taqman-Low Density Array to Predict Outcome in HL Using Paraffin Embedded Samples

  • Associations between Plasma Levels and Promoter Genotypes of IL-10 and IL-6 with Patient Characteristics and Outcome in HL

Session details 17:30–18:45
Main Program

Key Note Lecture

Room:Großer Saal
  • 17:30

    The Role of Innate Immunity in Cancer Progression

Session details 19:00–20:00
Satellite Symposium

Therapy of HL: Efficacy and Long Term Safety

Room:Großer Saal
  • 19:00

    Glycosylated G-CSF Mobilises More Clonogenic Progentiors than Non-Glycosylated G-CSF

  • Treatment Associated Long Term Toxicity in HL Patients

Tuesday 06.11.2007

Workshop Scientific Session Satellite Symposium Main Program
Session details 08:30–10:00
Scientific Session 8

Radiotherapy

Room:Großer Saal
  • 08:30

    Dose and Field Size: the EORTC Experience

  • Dose and Field Size: the GHSG Experience

  • Radioimmunotherapy (RIT) Applied to HL – a Useful Tool?

  • Yttrium-90 Radiolabeled Humanized Anti- CD25 Monoclonal Antibody, Daclizumab Provides Effective Therapy for Refractory and Relapsed HL

  • Involved Node Radiotherapy: Impact on Dose to PTV and Organs at Risk

  • Chemotherapy Alone versus Chemotherapy Plus Radiotherapy for Early Stage HL

Session details 10:30–12:00
Scientific Session 9

Allogenetic Transplantation

Room:Großer Saal
  • 10:30

    Overview on Transplantation Strategies

  • Do we Need Allogeneic Transplantation in HL?

  • New Frontiers in Allogeneic Transplantation for HL

  • Reduced Intensity Allogeneic Stem Cell Transplantation (RIC-Allo) for Refractory / Relapsed HL. Preliminary Results of an EBMT Prospective Trial

  • Workshop Report

Session details 12:15–13:45
Satellite Symposium

Role of Gemcitabine in the Treatment of Hodgkins Lymphoma

Room:Großer Saal
Session details 14:00–15:30
Scientific Session 10

PET

Room:Großer Saal
  • 14:00

    PET-CT for Treatment Response Assessment in Lymphoma

  • PET for Early Response Adapted Therapy

  • Current Role and Future of PET in HL

  • FDG-PET for Assessment of Residual Tissue after Completion of Chemotherapy in HL – Report on the 2nd Interim Analysis of the PET Investigation in the Trial HD15 of the GHSG

  • Early Interim FDG-PET Overshadows the Prognostic Role of IPS in Advanced-stage HL Treated by Conventional ABVD Therapy

  • Interim Results of a UK NCRI Randomised Trial Comparing Involved Field Radiotherapy with No Further Treatment after 3 Cycles ABVD and a “Negative” PET Scan in Clinical Stages IA/IIA

Session details 16:00–17:30
Scientific Session 11

Advanced Stages HL

Room:Großer Saal
  • 16:00

    North America: Cooperative Groups

  • EORTC

  • GHSG

  • Phase-II Study of Rituximab Plus ABVD for the Treatment of Newly Diagnosed Patients with Advanced Stage Classical HL

  • High-dose Therapy and ASCT versus Conventional Therapy for Patients with Advanced HL Responding to Front-line Therapy: Long Term Results

  • ABVD vs. COPPEBVCAD (CEC) vs. BEACOPP for the Initial Treatment of Patients with Advanced HL. Preliminary Results of HD2000 GISL Trial

Session details 17:30–18:45
Main Program

Closing Remarks

Room:Großer Saal
Session details 19:00
Main Program

Speakers Dinner

Room:tba

Wednesday 07.11.2007

Workshop Scientific Session Satellite Symposium Main Program
Session details 08:30–10:00
Workshop 6

For Young Oncologists

Room:tba

Basement

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Basement Wardrobe Stair to Ground Floor Stair to Ground Floor Weinkeller Basement

First Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of First Floor Stair to Ground Floor Stair to Ground Floor Großer Saal Isabellensaal First Floor

Dorint Hotel: Ground Level

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Dorint Hotel: Ground Level Stair to Ground Floor Stair to Ground Floor Go to First Floor Pipin II Pipin I Dorint Hotel: Ground Level

Dorint Hotel: First Floor

Allocations

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Floor plan of Dorint Hotel: First Floor Go to Ground Level Martin & Augustin Severin Dorint Hotel: First Floor

Exhibition

shift key

Hold SHIFT key while scrolling to zoom the map.

Hold ALT key while scrolling to rotate the map.

pinch-gesture

Use two fingers to zoom, move, or rotate the map.

Map of the exhibition. Map of the First Floor showing the location of 0 exhibitors. Stair to Ground Floor Stair to Ground Floor Großer Saal Isabellensaal

Not Found

Back to start